

Introducing Fitzpatrick's



www.BiologicsHQ.com

BiologicsHQ is a new interactive web database that provides metrics and comprehensive analysis of aBLA activity, USPTO post grant proceedings and patent litigation for CDER-listed / 505(b)(2) biologic drugs.

BiologicsHQ Search

Free and predictive text search of the BiologicsHQ database



METHODOLOGY CONTACT US POWERED BY **Fitzpatrick**

[BIOLOGICSHQ SEARCH](#) [NEWS](#) [STATISTICS](#) [BIOLOGICSHQ TEAM](#) [RESOURCES](#) [SUBSCRIBE](#)

BiologicsHQ Search

Information contained in the Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book. Product and Company page search results are reported for FDA-approved indications, aBLA and 505(b)(2) activity, approved foreign biosimilars, IPRs and U.S. litigations.

Enter Keywords

SEARCH

SEARCH BY:

Brand Name

ABP-215
Actemra®
Actimmune®
Activase® / Cathflo® Activase®
Adcetris®
Aldurazyme®
Alferon N Injection®
Amjevita
Amphadase®
Anthem®
Aranesp®
Arcalyst®
Arzerra®
Avastin®

Scientific Name

abatacept
abciximab
abobotulinumtoxinA
adalimumab
adalimumab-atto
ado-trastuzumab emtansine
afibercept
agalsidase beta
albiglutide
aldesleukin
alemtuzumab
alglucosidase alfa
alirocumab
alteplase



Company Name

ABBOTT
ABBVIE
ACCORD HEALTHCARE
ACTAVIS
ADVANCE BIOFACTURES
AKORN
ALEXION
ALLERGAN
AMGEN
AMPHASTAR PHARMACEUTICALS
AMYLIN PHARMS
APOTEX
AUXILIUM
BAUSCH AND LOMB

Search by biologic drug brand, scientific or company name

BiologicsHQ Statistics

Up-to-date metrics on biologics related USPTO post grant proceedings and patent litigations



BiologicsHQ Company Pages
provide information about
biologic drug licensors

BiologicsHQ Product Pages
provide information for CDER-listed /
505(2)(b) biologic drugs

CELLTRION

FDA-Approved Biologics and Pending Applications

Inflextra®
Infliximab-dyyb
aBL 125544

Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada
Remsima (Celltrion) (January-2014)

Biosimilars Approved In The E.U.
Remsima (Celltrion) (September-2013)
Truxima (Celltrion) (February-2017)

Biosimilars Approved In Japan
Infliximab BS (Remsima) (Celltrion / Nippon Kayaku) (July-2014)

Biosimilars Approved In South Korea
Herzuma (CT-P6) (Celltrion) (January-2014)
Remsima (Celltrion) (July-2012)
Truxima (CT P10) (Celltrion) (November-2016)

Inter Partes Review Proceedings

Herceptin®
IPR2017-00959
IPR2017-01121
IPR2017-01122
IPR2017-01139
IPR2017-01140

Rituxan®
IPR2015-01733
IPR2015-01744
IPR2016-01614
IPR2016-01667
IPR2017-01093
IPR2017-01094
IPR2017-01095
IPR2017-01227
IPR2017-01229
IPR2017-01230

U.S. BPCIA / Biosimilar Litigation

Remicade®
1:14-cv-02256 (S.D.N.Y.)
1:14-cv-11613 (D. Mass.)
1:14-cv-07049 (S.D.N.Y.)
1:15-cv-10698 (D. Mass.)
1:16-cv-00071 (N.D. Utah)
1:16-cv-11117 (D. Mass.)

Related News Articles



The U.S. Biosimilars Market is Heating Up: Guidance from the Federal Circuit is Expected Late Spring

Robert S. Schwartz, Ph.D.; Corinne E. Atton
April 6, 2015

Click to view
information
concerning
IPRs

Click to view
information
concerning
patent
litigations

Click to view
“Spotlight On”
report for
this drug

Humira® (adalimumab)

BL 125057

U.S. License Holder:	Date of License:	Last Update:
AbbVie Inc.	December-31-2002	April-28-2017

FDA-Approved Indications

HUMIRA (adalimumab) is a tumor necrosis factor (TNF) blocker indicated for treatment of:

Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA;

Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older;

aBLA / 505(b)(2) Activity

aBLA / 505(b)(2) Approved by FDA
Amjevita: Amgen (September-2016)

aBLA / 505(b)(2) Accepted by FDA
BI 695501 Boehringer Ingelheim (January-2017)

Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.
Amgevita / Solymbic (Amgen) (March-2017)

Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2017-00827 / IPR2017-01009

IPR2017-00826 / IPR2017-01008

IPR2017-00823

U.S. BPCIA / Biologics Litigation

PACER

Case No(s):

1:16-cv-00666 (D. Del.)

2:16-cv-00322 (E.D. Va.)

Related News Articles



Spotlight On Humira® (adalimumab)

Corinne E. Atton; April M. Breyer; Whitney L. Meier
April 10, 2017

For More Information On:
www.BiologicsHQ.com

April M. Breyer
(212) 218-2561

Corinne E. Atton
(212) 218-2212

**Fitzpatrick's Biotechnology/
Biologics Group:**

Robert S. Schwartz, Ph.D.
(212) 218-2298

Brendan M. O'Malley, Ph.D.
(212) 218-2249

**Business Development
& Marketing:**

Linda Ficano
(212) 218-2284